Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML Study IV

Blood

Volumn 126, Issue 1, 2015, Pages 42-49

  Saußele, Susanne ^a   Krauß, Marie Paloma ^a   Hehlmann, Rüdiger ^a   Lauseker, Michael ^b   Proetel, Ulrike ^a   Kalmanti, Lida ^a   Hanfstein, Benjamin ^a   Fabarius, Alice ^a   Kraemer, Doris ^c   Berdel, Wolfgang E ^d   Bentz, Martin ^e   Staib, Peter ^f   Wit De, Maike ^g   Wernli, Martin ^h   Zettl, Florian ⁱ   Hebart, Holger F ^j   Hahn, Markus ^k   Heymanns, Jochen ^l   Schmidt Wolf, Ingo ^m   Schmitz, Norbert ⁿ   Eckart, Michael J ^o   Gassmann, Winfried ^p   Bartholomäus, Andrea ^q   Pezzutto, Antonio ^r   Leibundgut, Elisabeth Oppliger ^s   Heim, Dominik ^t   Krause, Stefan W ^u   Burchert, Andreas ^v   Hofmann, Wolf Karsten ^a   Hasford, Joerg ^b   Hochhaus, Andreas ^w   Pfirrmann, Markus ^b   Müller, Martin C ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^f ST ANTONIUS HOSPITAL ESCHWEILER   (Germany)

^g VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^h CANTONAL HOSPITAL AARAU   (Switzerland)

ⁱ UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^j Zentrum für Innere Medizin   (Germany)

^k Ambulantes Onkologie Zentrum   (Germany)

^l Praxisklinik fur Hamatologie und Onkologie   (Germany)

^m UNIVERSITY HOSPITAL BONN   (Germany)

ⁿ DEPARTMENT OF CARDIOLOGY   (Germany)

^o Internistische Schwerpunktpraxis   (Germany)

^p St Marien Krankenhaus Siegen gem GmbH   (Germany)

^q ST BERNWARD KRANKENHAUS   (Germany)

^r CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^s UNIVERSITY OF BERN   (Switzerland)

^t UNIVERSITY HOSPITAL BASEL   (Switzerland)

^u UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^v UNIVERSITY HOSPITAL MARBURG   (Germany)

^w JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BENZALKONIUM CHLORIDE; CYTARABINE; HEMOGLOBIN; IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BENIGN TUMOR; BLAST CELL CRISIS; BLOOD CLOTTING DISORDER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; COMORBIDITY; CONGESTIVE HEART FAILURE; CYTOGENETICS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERURICEMIA; INFECTION; INFLAMMATORY BOWEL DISEASE; INTERMEDIATE RISK PATIENT; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LEUKEMIA REMISSION; LOW DRUG DOSE; LUNG DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL VASCULAR DISEASE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; THYROID DISEASE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; COMBINED MODALITY THERAPY; COMORBIDITY; CYTARABINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMATINIB MESYLATE; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937879454     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-617993     Document Type: Article

References (31)

1. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-a in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29(12):1634-1642.
2. Hehlmann R, Müller MC, Lauseker M, et al. Deep Molecular Response (MR4.5) is reached by the majority of imatinib-treated patients, predicts survival, and is achieved faster by optimized highdose imatinib-results from the randomized CMLStudy IV. J Clin Oncol. 2014;32(5):415-423.
3. Saglio G, Kim DW, Issaragrisil S, et al; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-2259.
4. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
5. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronicphase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123-1129.
6. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494-500.
7. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012; 26(10):2197-2203.
8. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
9. Ording AG, Garne JP, Nyström PM, Frøslev T, Sørensen HT, Lash TL. Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis-a Danish nationwide matched cohort study. PLoS ONE. 2013;8(10): E76013.
10. Goede V, Cramer P, Busch R, et al; German CLL Study Group. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: Results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99(6): 1095-1100.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5): 373-383.
12. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-1251.
13. Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res. 2009;33(12):1594-1598.
14. Breccia M, Federico V, Loglisci G, Salaroli A, Serrao A, Alimena G. Evaluation of overall survival according to myelodysplastic syndromespecific comorbidity index in a large series of myelodysplastic syndromes. Haematologica. 2011;96(10):e41-e42.
15. Gugliotta G, Castagnetti F, Fogli M, Cavo M, Baccarani M, Rosti G. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Expert Rev Hematol. 2013;6(5):563-574.
16. Breccia M, Latagliata R, Stagno F, et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica. 2011;96(10):1457-1461.
17. Rousselot P, Cony-Makhoul P, Nicolini F, et al; French Intergroup For Chronic Myelogenous Leukemia (Fi-LMC). Long-term safety and efficacy of imatinib mesylate (Gleevec-) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study. Am J Hematol. 2013;88(1):1-4.
18. Saussele S, Lauseker M, Gratwohl A, et al; German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010; 115(10):1880-1885.
19. Baccarani M, Saglio G, Goldman J, et al; European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108(6):1809-1820.
20. Baccarani M, Cortes J, Pane F, et al; European LeukemiaNet. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.
21. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood. 2011;118(3):686-692.
22. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
23. Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172-2175.
24. Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV [published online ahead of print February 13, 2015]. Leukemia.
25. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980; 45(8):2220-2224.
26. Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia. 2011;25(9):1433-1438.
27. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: Competing risks and multi-state models. Stat Med. 2007;26(11):2389-2430.
28. Kalmanti L, Saussele S, Lauseker M, et al; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft f ür Klinische Krebsforschung (SAKK). Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: Results from the randomized CML study IV. Ann Hematol. 2014;93(1):71-80.
29. Pfirrmann M, Saussele S, Baccarani M, et al. Long-term survival outcome and prognosis in 2277 patients with chronic myeloid leukemia allocated to first-line imatinib treatment-new results from the EUTOS in-study registry. Haematologica. 2013;98(s1):298.
30. Pfirrmann M, Saussele S, Baccarani M, et al. Survival and prognosis in patients with first-line imatinib treatment under particular consideration of death due to chronic myeloid leukemia. Blood. 2014;124(21):153.
31. Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2009;23(3):602-604.